News
ALDX
1.800
+1.12%
0.020
Weekly Report: what happened at ALDX last week (0406-0410)?
Weekly Report · 21h ago
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
PR Newswire · 1d ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 3d ago
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade)
Seeking Alpha · 4d ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Barchart · 6d ago
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately
PR Newswire · 6d ago
Weekly Report: what happened at ALDX last week (0330-0403)?
Weekly Report · 04/06 10:26
Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
TipRanks · 04/03 15:34
ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
PR Newswire · 04/03 12:40
ADLX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Aldeyra Therapeutics, Inc.
PR Newswire · 04/02 21:43
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
TipRanks · 04/01 20:58
ALDEYRA THERAPEUTICS INC - PAYS OFF $15 MLN OUTSTANDING BORROWINGS, TERMINATES HERCULES CREDIT FACILITY - SEC FILING
Reuters · 04/01 20:27
Aldeyra Therapeutics repays $15 million, terminates Hercules credit facility
Reuters · 04/01 20:25
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 03/31 23:17
INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP
Barchart · 03/31 19:00
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Barchart · 03/31 15:33
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Barchart · 03/31 15:25
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Aldeyra Therapeutics, Inc. Investors – ALDX
Barchart · 03/30 20:14
Weekly Report: what happened at ALDX last week (0323-0327)?
Weekly Report · 03/30 10:27
Monday 3/23 Insider Buying Report: GCBC, ALDX
NASDAQ · 03/23 19:32
More
Webull provides a variety of real-time ALDX stock news. You can receive the latest news about Aldeyra Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.